Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of theaflavin TF3 to preparation of PK (plasma kallikrein) inhibitor and medicines for NAFLD (non-alcoholic fatty liver disease) treatment

A technology of theaflavins and inhibitors, which is applied in the field of theaflavins TF3 for the preparation of PK inhibitors and drugs for the treatment of NAFLD, which can solve the problems of complex extraction of mixture targets and insufficient effect of active ingredients, so as to reduce lipid Accumulation, easy to use effect

Inactive Publication Date: 2020-02-28
TEA RES INST GUANGDONG ACAD OF AGRI SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in general, water extracts or alcohol extracts of tea are used for activity research. Due to the complex targets of the extracted mixture components, the effect of effective components is not obvious enough.
At present, there is no research on the prevention, alleviation and treatment of NAFLD by tea monomer substances, and there is no related research on the specific target PK of tea active monomers on NAFLD patients or at the cellular level.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of theaflavin TF3 to preparation of PK (plasma kallikrein) inhibitor and medicines for NAFLD (non-alcoholic fatty liver disease) treatment
  • Application of theaflavin TF3 to preparation of PK (plasma kallikrein) inhibitor and medicines for NAFLD (non-alcoholic fatty liver disease) treatment
  • Application of theaflavin TF3 to preparation of PK (plasma kallikrein) inhibitor and medicines for NAFLD (non-alcoholic fatty liver disease) treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] The pharmaceutical preparation described in this example uses theaflavin-3,3'-gallate (TF3) as the active ingredient, and is prepared into a clinically acceptable tablet by adding conventional excipients according to a conventional process.

Embodiment 2

[0042] The pharmaceutical preparation described in this example uses theaflavin-3,3'-gallate (TF3) as the active ingredient, and is prepared into clinically acceptable capsules by adding conventional excipients according to conventional techniques.

Embodiment 3

[0044] The pharmaceutical preparation described in this example uses theaflavin-3,3'-gallate (TF3) as the active ingredient, and is prepared into clinically acceptable pills by adding conventional excipients according to conventional techniques.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of pharmaceutical preparations and particularly relates to application of theaflavin TF3 to preparation of a PK (plasma kallikrein) inhibitor and medicinesfor NAFLD (non-alcoholic fatty liver disease) treatment. By a direct inhibition effect of tea monomer theaflavin TF3 (theaflavin-3, 3'-gallate) on PK targets in NAFLD liver cells, TF3 is capable of remarkably inhibiting PK enzymatic activity and further remarkably activating AMPK signal routing after PK inhibition to reduce lipid synthesis protein expression and activate or stimulate lipidolysisprotein expression and is also capable of reducing accumulation of intracellular lipids through PK activity inhibition. Therefore, the theaflavin TF3 can be used as a newly discovered PK inhibitor with a certain regulation function in fat metabolism pathway, plays a key role in NAFLD improvement, has an effect of NAFLD treatment or alleviation and can be applied to medicines for NAFLD prevention,treatment or alleviation.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to the use of theaflavin TF3 in the preparation of PK inhibitors and drugs for treating NAFLD. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is defined as the excessive accumulation of fat in the liver not caused by excessive alcohol consumption. According to research, NAFLD is closely related to symptoms of metabolic syndrome such as obesity, type 2 diabetes, hypertension, kidney disease and dyslipidemia, and is an important factor affecting the quality of life and life expectancy of patients. Cirrhosis and even liver cancer. With the changes in people's diet and living habits, the incidence of NAFLD has gradually increased in recent years, and the incidence rate is about 25% worldwide. In my country, the incidence rate of adults is about 15%, and the incidence rate of obese children is even as high as 68.2%. %, has become ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/353A61P1/16
CPCA61K31/353A61P1/16
Inventor 张文姬孙世利孙伶俐陈若虹黎秋华赖幸菲
Owner TEA RES INST GUANGDONG ACAD OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products